The trial compared Spravato (esketamine nasal spray) to quetiapine extended-release, both in combination with a continuing SSRI or SNRI.
Home
Tetravalent Dengue Vaccine Candidate Granted Priority Review
The BLA is supported by data from the pivotal TIDES trial which included over 20,000 patients 4 to 16 years of age.
First Gene Therapy for Hemophilia B Gets FDA Approval
The approval was based on data from the HOPE-B trial that included 54 male participants with severe or moderately severe hemophilia B.
Continuing ACE Inhibitors Despite Potassium Change Can Have Benefits
Stopping renin-angiotensin-aldosterone inhibitors after hyperkalemia may offset their potential clinical benefits, according to investigators.
Guidance Provided for Identifying, Managing CP in Primary Care
A patient- and family-centered care team should be established by engaging pediatricians with the family and specialists
Disparities Seen in Treatment of Middle Ear Infections in US Children
Socially disadvantaged children less likely to receive treatment for recurrent or suppurative otitis media
USPSTF Recommends Screening for Latent TB Infection
Task force recommends screening asymptomatic adults at increased risk for latent TB infection
FDA: Prolia Use in Dialysis Patients May Cause Severe Hypocalcemia
According to a long-term safety study and a separate FDA internal study, Prolia had an increased risk of hypocalcemia in patients with advanced kidney disease on dialysis.
Efgartigimod SC Formulation Gets Priority Review for Myasthenia Gravis
Efgartigimod is currently marketed under the trade name Vyvgart and is available as a single-dose vial for intravenous infusion after dilution.
Want to read more?
Please login or register first to view this content.
